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Depression is common in people with chronic kidney disease (CKD). When diagnosed via a gold 
standard semi-structured psychiatric interview by culturally-competent staff, depression affects one 
fifth to one quarter of people with CKD, whether in receipt of maintenance dialysis, with non-dialysis 
treated CKD, or with a functioning transplant (respective prevalence rates 22.8 (95% confidence 
interval (CI) 18.6 to 27.6)%, 21.4 (95%CI 11.1 to 37.2)% and 25.7 (95%CI 12.8 to 44.9)%)1. These 
frequencies are clearly in excess of the average population lifetime risk of ~ 9%2. Potential reasons 
for the high rates of depression in end stage kidney disease (ESKD) include the overlap of some risk 
factors for both conditions, the alteration of physiological processes associated with ESKD and the 
psychosocial consequences of living with ESKD3. Depression in people receiving dialysis is associated 
with lower quality of life, increased hospitalisations and, likely shortened survival3.  
Despite its frequency and impact we have little evidence to guide management of depression in 
people with CKD. There are two Cochrane systematic reviews on antidepressant treatment4 and 
psychosocial interventions5 for depression in people on haemodialysis to guide practice. 
Unfortunately, the psychosocial interventions review includes no trials. The antidepressant review 
includes one randomised, placebo-controlled trial (RCT) with depression as an endpoint. This trial of 
sertraline included only 43 participants6 and showed a statistically significant lower Beck Depression 
Inventory (BDI) scale7 mean score at the end of treatment in the sertraline group of -7.50 (95% CI -
11.94 to -3.06). In one other trial 44 participants were randomised to receive citalopram or 
‘psychological training’ and showed no differential evidence of benefit8. 
So it was with great anticipation that we read the two trials in this edition of CJASN. Friedli et al9 
explored the feasibility of conducting a RCT of sertraline in people on haemodialysis with major 
depressive disorder diagnosed via a structured psychiatric interview (the MINI)10. The results of their 
pilot RCT outline the difficulties of conducting trials of depression in people with CKD in agonising 
detail.  After screening 1,353 patients, 231 participants were identified on the basis of high scores on 
the BDI-II. Of these, 30% were on some form of pharmaceutical or non-pharmaceutical therapy – a 
figure that further reduced the eligible population but one that also indicates the number receiving 
ineffective treatment strategies. With only 50% of the recruitment target of 60 able to be 
randomised to sertraline or placebo, the next challenge was the immediate drop in BDI-II scores in 
all participants at the first post-randomisation follow-up indicating spontaneous recovery, regression 
to the mean or possibly the therapeutic advantage associated with involvement in a trial. The next 
challenge was the uneven drop-out with nearly half of intervention participants (7/15) dropping out 
by 4 months compared with only 2 of the 15 control patients. The small numbers involved prevent 
speculation on the degree to which this was due to drug tolerability or the play of chance. Given the 
challenges, the authors correctly identify the negative result of their study is not definitive and 
conclude further trials on the treatment of major depression in this population are warranted. 
Pena et al11 report secondary analyses of data from the SMILE trial; an RCT comparing the 
effectiveness of two 12-month pain, sexual dysfunction and depression symptom management 
strategies in adults receiving chronic haemodialysis: a feedback intervention (not covered in this 
edition’s article) and a management intervention. The SMILE trial began with monthly observational 
surveys documenting participants’ symptoms of pain, sexual dysfunction and depression12 (assessed 
using the interviewer-administered 9-item Patient Health Questionnaire (PHQ-9)13). The ‘feedback 
intervention’ included feedback of participants’ symptom scores, for those with one or more 
symptoms of pain, sexual dysfunction or depression, and their respective guideline-based treatment 
modifications to participants’ renal providers. Five written guideline-based treatment algorithms 
were used for nociceptive pain, neuropathic pain, erectile dysfunction, female sexual dysfunction, 
and depression12. The renal provider (nephrologist and/or renal nurse practitioner/physician 
assistant) decided whether or not to implement the algorithm-defined treatment recommendations.  
In this edition Pena et al11 report the acceptance (by participants) and uptake (by renal providers) of 
depression-symptom management recommendations made by trial-specific nurses for those in the 
‘management intervention’ following the aforementioned treatment algorithm for depression. A 
trial-specific nurse preformed a history and medical examination, reviewed participants’ symptoms, 
and generated treatment recommendations for each symptom. The nurse contacted the renal 
provider to review participants’ symptoms and discuss the treatment recommendations. The patient 
or the renal provider could refuse the recommendations. Both interventions in SMILE achieved the 
same small but statistically significant decrease in depression symptoms from the observation phase 
to the end of the intervention.14  
It is not immediately obvious how we should interpret the results of the SMILE study11. It is possible 
that considering five treatment algorithms on a monthly basis over and above the management of 
CKD was excessively complex. The sheer number of treatment recommendations may have diluted 
any additional benefit of a trial-specific nurse providing the information. With multiple symptom 
targets, it is possible pain or sexual dysfunction may have been prioritised over depression by 
patients or clinicians. Alternatively, it may be that guideline-based algorithms are not effective for 
people with complex conditions.  
We believe trials in people with depression receiving dialysis are feasible because the altered 
physiology of ESKD and its associated polypharmacy create clear equipoise on the efficacy and 
harms of depression treatment. The publications in this issue should further strengthen equipoise. 
Recruitment presents the major challenge. Friedl et al recruited 30 patients from 5 units. The results 
are broadly comparable with that of the industry-sponsored EVOLVE trial, the largest completed 
dialysis trial, which recruited an approximate average of 10 patients per site with many sites 
recruiting fewer than 5 participants15. Large investigator networks, considerable industry 
sponsorship and/or substantial collaboration would be required for a definitive trial. 
A further challenge in clinical practice is accurately identifying depression. The gold standard 
diagnostic method is not accessible in most non-mental health clinical environments where simple, 
quick, self- or clinician-administered depression screening tools are often used. Generic depression 
screening tools substantially overestimate the prevalence of depression in dialysis patients by over 
70%, but only by 24% in CKD patients and <5% in transplant patients1. While depression screening 
tools are sensitive enough to identify fluctuations in depressive symptom burden, as illustrated in 
Friedl9 and Pena11, recruiting only participants with sustained high scores over multiple assessments 
would identify those with the greatest need of intervention. However, this would shrink the eligible 
trial populations further. 
Depression screening tools perform poorly in people receiving dialysis, in part, due to the 
overlapping constellation of symptoms common to depression and ESKD which include fatigue, 
altered sleep, and suppressed appetite. Depression screening tools were developed in general 
populations and were not designed to identify the cause of symptoms. A second reason may be the 
high rates of intermittent, distressing events that may appropriately elicit negative feelings. Just 
about every negative medical experience including cardiovascular events, cancer diagnoses, 
hospitalisations and impaired physical function are disproportionately higher among people with 
ESKD16-18. It is intriguing to note that a portion of those in SMILE11 with high scores on the PHQ-9 
refused depression treatment on the grounds of intercurrent events. Perhaps they ‘knew’ why they 
were experiencing a negative affect and were in effect refuting a diagnosis of endogenous 
depression. Lastly, people on dialysis experience substantial kidney disease-related losses, a 
phenomenon also associated with adverse scores on depression screening tools19.  
These competing factors of high symptom burden, intercurrent events and kidney disease-related 
losses should not be dismissed purely as ‘competing risks’ for high scores on depression screening 
tools. The association between these events and psychiatrist-diagnosed depression has been 
demonstrated suggesting these events may be predisposing factors for depression3,19. However, 
these competing factors do add to the complexity of identifying a ‘pure’ depression trial cohort as 
these papers illustrate.  
While the reports in this edition highlight the challenges associated with conducting trials of 
depression treatments in dialysis patients, both papers provide valuable information that should 
inform the design of future trials rather than dissuade researchers. The lack of observed differential 
benefit in the completed trials provides a clear justification for broadening future trials to include 
patients already on antidepressants, including recruiting those willing to undergo a wash-out period 
as suggested by Friedl et al9. A de-prescribing trial model for dialysis patients taking SSRIs is 
justifiable given their lack of clear efficacy and the potential for side effects. Participants could be 
recruited on the basis of sustained high screening tool scores rather than requiring formal 
psychiatric assessment. Apart from facilitating recruitment this method would better reflect how 
patients are selected for treatment in most primary health settings. Other trial designs that may be 
appealing for participants may include randomisation to immediate or delayed start.  
The challenges facing depression treatment trials in people on dialysis may reflect the low priority 
placed on depression. In the wider context there is poor recognition of depressive symptoms, an 
unwillingness of patients to seek help and a stigma attached to a diagnosis of depression and its 
treatment. The presence of depression may be eclipsed for patients, carers and clinicians by 
intensive medical intervention, intercurrent comorbidities, and high rates of unwelcome events. The 
deprioritisation of depression and the challenges reported in this edition could understandably leave 
many feeling trials of depression interventions in dialysis are not feasible. However the patients’ 
concerns vocalised through the SONG initiative ask for research into living well on dialysis, rather 
than just surviving20. Arguably, a safe, effective, low cost treatment for managing depression would 
realise a substantial and significant improvement in the lived experience.  
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